- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Experimental Drug to Fight Ebola Arrives in Liberia
NBC News reported that an “experimental drug” has arrived in Liberia, to be tried on one infected charity worker from the US. No confirmations have been made as to which drug is being used but there are several in development, including Tekmira Pharmaceuticals’ TKM-Ebola Phase I which was recently put on hold as the company addresses US Food and Drug Administration concerns.
NBC News reported that an “experimental drug” has arrived in Liberia, to be tried on one infected charity worker from the US. No confirmations have been made as to which drug is being used but there are several in development, including Tekmira Pharmaceuticals’ TKM-Ebola Phase I which was recently put on hold as the company addresses US Food and Drug Administration concerns.
As quoted in the article:
“All we know and can say it is an experimental drug among several options that was the most promising,” said Bruce Johnson, president of Serving in Mission USA. “Doctors on the ground in Liberia with Samaritan’s Purse and SIM were involved in the decision-to-use process, along with the consent of the patients.
Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, said he also had no idea which treatment the group may be using.
“The sad fact is we don’t have any proven treatment for Ebola. We don’t have any proven vaccine against Ebola,” he told NBC News.
Companies may provide experimental drugs for use on a compassionate basis in cases of dire need. In this case, U.S. regulators may not need to become involved because the patients are not in the United States.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.